GLR1061

GLR1061: sourced facts only. name: "GLR1061 is a B7H3 targeting ADC comprised of a humanized IgG1 monoclonal antibody, a cleavable linker and a novel DNA topoisomerase I inhibitor." [DOI:10.1158/1538-7445.am2025-2878]; target: "GLR1061 is a B7H3 targeting ADC comprised of a humanized IgG1 monoclonal antibody, a cleavable linker and a novel DNA topoisomerase I inhibitor." [DOI:10.1158/1538-7445.am2025-2878]; developer: "Gan & Lee Pharmaceuticals, Beijing, China." [DOI:10.1158/1538-7445.am2025-2878]; modality: "GLR1061 is a B7H3 targeting ADC comprised of a humanized IgG1 monoclonal antibody, a cleavable linker and a novel DNA topoisomerase I inhibitor." [DOI:10.1158/1538-7445.am2025-2878]; stage: "In addition, in the CDX model of co-culture of antigen-positive and antigen-negative cells, GLR1061 exhibited much stronger bystander activity than DS7300, which was expected to overcome tumor heterogeneity and effectively eliminate cancer cells with different antigens expressions." [DOI:10.1158/1538-7445.am2025-2878]